Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL333015 | 0.93 | ADRA2A (0.50) | CYP19A1CA1CA12CA2CA9 | |
| SCHEMBL22812976 | 0.89 | CA1 (0.41) | CYP19A1CA1CA12CA2CA9 | |
| SCHEMBL25886908 | 0.88 | CA1 (0.44) | CYP19A1CA1TDP1ADRA2AADRA1A | |
| SCHEMBL14672499 | 0.88 | DGKA (0.48) | CYP19A1CA1CA12CA2CA9 | |
| SCHEMBL14308492 | 0.88 | CA1 (0.44) | CYP19A1CA1TDP1ADRA2AADRA1A | |
| SCHEMBL249563 | 0.88 | DGKA (0.54) | CYP19A1CA1CA12CA2CA9 | |
| SCHEMBL494501 | 0.86 | DGKA (0.57) | CYP19A1CA1CA12CA2CA9 | |
| SCHEMBL11051092 | 0.86 | CA1 (0.43) | CYP19A1CA1CA12CA2CA9 | |
| SCHEMBL494939 | 0.86 | DGKA (0.57) | CYP19A1CA1CA12CA2CA9 | |
| SCHEMBL4160276 | 0.86 | DGKA (0.47) | CYP19A1CA1CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | claimed |
| CN-110981873-B | Preparation method for synthesizing pyrroloquinoline quinone by five-step method | 江西农业大学 | 2025-01-24 | — | — | CN | disclosed |
| CN-110799179-A | Solid composition comprising iodine reagent and sodium chloride with improved water solubility and antiviral and antibacterial composition for eye, oral cavity, nasal cavity or inhalation comprising aqueous solution thereof | 富陆凯米有限责任公司 | 2020-02-14 | — | — | CN | disclosed |
| CN-106632761-B | A kind of Narrow Molecular Weight Distribution polypropylene and preparation method thereof | 中国石油化工股份有限公司 | 2019-06-28 | — | — | CN | disclosed |
| US-20180208590-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-9944632-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20180016269-A1 | NOVEL COMPOUNDS AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2018-01-18 | — | — | US | disclosed |
| CN-107417818-A | It is a kind of for the catalytic component of olefinic polymerization, preparation method and catalyst | 北京利和知信科技有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-104755510-B | Ziegler natta catalyst system of internal donor and preparation method thereof is used as comprising 1,2 phenylene diester | 印度石油有限公司 | 2017-11-07 | — | — | CN | disclosed |
| CN-107033591-A | A kind of high temperature resistance polyester imine nanometer ultrathin membrane and preparation method thereof | 陕西科技大学 | 2017-08-11 | — | — | CN | disclosed |
| US-20150197494-A1 | NO-RELEASING NITROOXY-METHYLENE-LINKED-COXIB CONJUGATES | EUCLISES PHARMACEUTICALS INC (US) | 2015-07-16 | — | — | US | disclosed |
| US-9044464-B2 | No-releasing guanidine-coxib anti-cancer agents | Euclises Pharmaceuticals, Inc. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8859781-B2 | No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents | Euclises Pharmaceuticals, Inc. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8765809-B2 | Ester derivative and use thereof | AJINOMOTO CO., INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-20140018403-A1 | NO-RELEASING GUANIDINE-COXIB ANTI-CANCER AGENTS | Euclises Pharmaceuticals, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20140018544-A1 | NO-RELEASING NONOATE(NITROGEN-BOUND)SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | Euclises Pharmaceuticals, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20130053441-A1 | NOVEL ESTER DERIVATIVE AND USE THEREOF | AJINOMOTO CO., INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-8212068-B2 | Ester derivative and use thereof | AJINOMOTO CO., INC. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-20090170942-A1 | ESTER DERIVATIVE AND USE THEREOF | AJINOMOTO CO. INC (JP) | 2009-07-02 | — | — | US | disclosed |
| JP-2004318111-A | COLORED PHOTOSENSITIVE RESIN COMPOSITION | SUMITOMO CHEM CO LTD | 2004-11-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018544-A1 | NO-RELEASING NONOATE(NITROGEN-BOUND)SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | NOS1, NOS2, PTGS1 | CYP19A1 467/4885CA1 3639/4885CA12 2841/4885 |
| US-20180016269-A1 | NOVEL COMPOUNDS AND USES THEREOF | ESR2, ESRRB, ESRRA | CYP19A1 10/4885CA1 3713/4885CA12 2268/4885 |
| US-20180208590-A1 | NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESRRG, ESR1 | CYP19A1 7/4885CA1 3999/4885CA12 3469/4885 |
| US-20140018403-A1 | NO-RELEASING GUANIDINE-COXIB ANTI-CANCER AGENTS | GUCY1B1, ARGLU1, ARG1 | CYP19A1 739/4885CA1 4517/4885CA12 4019/4885 |
| US-20130053441-A1 | NOVEL ESTER DERIVATIVE AND USE THEREOF | MEP1A, CES2, MEP1B | CYP19A1 7/4885CA1 1613/4885CA12 860/4885 |
| US-20090170942-A1 | ESTER DERIVATIVE AND USE THEREOF | MEP1A, CES2, F8 | CYP19A1 6/4885CA1 1073/4885CA12 736/4885 |
| US-20150197494-A1 | NO-RELEASING NITROOXY-METHYLENE-LINKED-COXIB CONJUGATES | NOS1, NOS2, PTGS1 | CYP19A1 190/4885CA1 4161/4885CA12 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.